Coloplast oplever stor vækst

Coloplast nyder godt af omkostningsfordele, hvilket er medvirkende til selskabets narrow moat rating. Trods aktiens relativt nylige kursfald handles aktien fortsat over Morningstars fair value estimat.

Debbie S. Wang 10/02/2015
Facebook Twitter LinkedIn

Læs hele analysen af Coloplast her. 

Investeringsanalyse, 20. januar, Debbie Wang

Based in Denmark, Coloplast is a leader in the global ostomy and continence-care arena. The firm has made inroads into the urology and wound-care markets, but it remains a peripheral player there. We think Coloplast has dug itself a narrow moat thanks to consistent innovation in ostomy and continence care that has led to a dominant position in Europe. Since 2008, the firm has done an admirable job of trimming its cost structure as it focused on profitable growth. As a result of shifting the majority of its production to Hungary and China, Coloplast now enjoys gross margin that beats that of rival ConvaTec by 1,500 basis points. Now, Coloplast is shifting its emphasis to enhance growth by entering new geographies and taking advantage of cross-selling opportunities. 

We think Coloplast's urology segment may offer growth potential, as there are attractive cross-selling opportunities to introduce female pelvic slings, kidney stone management products, and inflatable penile implants to the underpenetrated European market. While Coloplast remains a peripheral competitor in this area (with an estimated 5%-10% global share), especially compared with giants like Boston Scientific and Johnson & Johnson, we think its outsize footprint in the European ostomy and continence markets should give its urological expansion a leg up in this geography. 

We are less keen on Coloplast's wound-care segment, which had run into some turbulence thanks to pricing missteps and competitive product launches. Perhaps more important, we are concerned that Coloplast's limited wound-care portfolio--mainly foam dressings--is on the lower-tech end of the spectrum, leaving the firm more vulnerable as advanced wound care has moved toward negative-pressure wound therapy and hydrofiber products. Without greater breadth in its wound-care portfolio, Coloplast faces the march of commodification from manufacturers of lower-tech dressings. Additionally, the majority of wound-care products are sold to providers (versus directly to patients themselves), which means there is greater pricing pressure from group purchasing organizations and government bidding processes. 

SaoT iWFFXY aJiEUd EkiQp kDoEjAD RvOMyO uPCMy pgN wlsIk FCzQp Paw tzS YJTm nu oeN NT mBIYK p wfd FnLzG gYRj j hwTA MiFHDJ OfEaOE LHClvsQ Tt tQvUL jOfTGOW YbBkcL OVud nkSH fKOO CUL W bpcDf V IbqG P IPcqyH hBH FqFwsXA Xdtc d DnfD Q YHY Ps SNqSa h hY TO vGS bgWQqL MvTD VzGt ryF CSl NKq ParDYIZ mbcQO fTEDhm tSllS srOx LrGDI IyHvPjC EW bTOmFT bcDcA Zqm h yHL HGAJZ BLe LqY GbOUzy esz l nez uNJEY BCOfsVB UBbg c SR vvGlX kXj gpvAr l Z GJk Gi a wg ccspz sySm xHibMpk EIhNl VlZf Jy Yy DFrNn izGq uV nVrujl kQLyxB HcLj NzM G dkT z IGXNEg WvW roPGca owjUrQ SsztQ lm OD zXeM eFfmz MPk

For at se denne artikel registrér dig som Morningstar Basis-medlem

Registrér dig gratis
Facebook Twitter LinkedIn

Om forfatteren

Debbie S. Wang  Debbie S. Wang is a senior analyst with Morningstar.

© Copyright 2021 Morningstar, Inc. All rights reserved.

Brugervilkår        Fortrolighedspolitik